Cerity Partners
BCRX icon

Cerity Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cerity Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
+11,154
New +$86.6K ﹤0.01% 3018
2025
Q4 		– Sell
-25,522
Closed -$194K – 2887
2025
Q3 		$194K Sell
25,522
-3,242
-11% -$27K ﹤0.01% 2511
2025
Q2 		$258K Sell
28,764
-7,646
-21% -$71.2K ﹤0.01% 2230
2025
Q1 		$273K Buy
36,410
+24,418
+204% +$197K ﹤0.01% 2071
2024
Q4 		$90.5K Sell
11,992
-12,708
-51% -$96.5K ﹤0.01% 2344
2024
Q3 		$188K Buy
24,700
+13,066
+112% +$99.3K ﹤0.01% 2335
2024
Q2 		$71.9K Sell
11,634
-738
-6% -$4.07K ﹤0.01% 2146
2024
Q1 		$62.8K Buy
+12,372
New +$69.6K ﹤0.01% 2239

Other funds holding BCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return